Literature DB >> 12151395

Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio.

Delphine Javelaud1, Francoise Besancon.   

Abstract

p21(WAF1) appears to be a major determinant of the cell fate in response to anticancer therapy. It was shown previously that HCT116 human colon cancer cells growing in vitro enter a stable arrest upon DNA damage, whereas cells with a defective p21(WAF1) response undergo apoptosis. Here we report that the enhanced sensitivity of HCT116/p21(-/-) cells to chemotherapeutic drug-induced apoptosis correlates with an increased expression of p53 and a modification of their Bax/Bcl-2 ratio in favor of the pro-apoptotic protein Bax. Treatment of HCT116/p21(-/-) cells with daunomycin resulted in a reduction of the mitochondrial membrane potential and in activation of caspase-9, whereas no such changes were observed in HCT116/p21(+/+) cells, providing evidence that p21(WAF1) exerts an antagonistic effect on the mitochondrial pathway of apoptosis. Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-alpha reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(+/+) cells. Enhancement of p53 expression after disruption of p21(WAF1) resulted from a stabilization of p53, which correlated with an increased expression of the tumor suppressor p14(ARF), an inhibitor of the ubiquitin ligase activity of Mdm2. In accordance with the role of p14(ARF) in p53 stabilization, overexpression of p14(ARF) in HCT116/p21(+/+) cells resulted in a strong increase in p53 activity. Our results identify a novel mechanism for the anti-apoptotic effect of p21(WAF1) consisting in maintenance of mitochondrial homeostasis that occurs in consequence of a negative control of p14(ARF) expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151395     DOI: 10.1074/jbc.M204497200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  p21Cip1 protection against hyperoxia requires Bcl-XL and is uncoupled from its ability to suppress growth.

Authors:  Peter F Vitiello; Rhonda J Staversky; Sean C Gehen; Carl J Johnston; Jacob N Finkelstein; Terry W Wright; Michael A O'Reilly
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 2.  The p53-MDM2 network: from oscillations to apoptosis.

Authors:  Indrani Bose; Bhaswar Ghosh
Journal:  J Biosci       Date:  2007-08       Impact factor: 1.826

3.  A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster.

Authors:  Xiao Ling Li; Toshifumi Hara; Youngeun Choi; Murugan Subramanian; Princy Francis; Sven Bilke; Robert L Walker; Marbin Pineda; Yuelin Zhu; Yuan Yang; Ji Luo; Lalage M Wakefield; Thomas Brabletz; Ben Ho Park; Sudha Sharma; Dipanjan Chowdhury; Paul S Meltzer; Ashish Lal
Journal:  Mol Cell Biol       Date:  2013-11-25       Impact factor: 4.272

4.  Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A.

Authors:  Romi Gupta; Yuying Dong; Peter D Solomon; Hiromi I Wettersten; Christopher J Cheng; Jin-Na Min; Jeremy Henson; Shaillay Kumar Dogra; Sung H Hwang; Bruce D Hammock; Lihua J Zhu; Roger R Reddel; W Mark Saltzman; Robert H Weiss; Sandy Chang; Michael R Green; Narendra Wajapeyee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

5.  p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG.

Authors:  Vijay S Thakur; A R M Ruhul Amin; Rajib K Paul; Kalpana Gupta; Kedar Hastak; Mukesh K Agarwal; Mark W Jackson; David N Wald; Hasan Mukhtar; Munna L Agarwal
Journal:  Cancer Lett       Date:  2010-05-04       Impact factor: 8.679

6.  Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2.

Authors:  Yi Xu; Xiaoyu Yang; Pinjing Zhao; Zhongyu Yang; Changhui Yan; Bin Guo; Steven Y Qian
Journal:  Free Radic Biol Med       Date:  2016-04-19       Impact factor: 7.376

7.  Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.

Authors:  M T de Bruijn; D A E Raats; F J H Hoogwater; W J van Houdt; K Cameron; J P Medema; I H M Borel Rinkes; O Kranenburg
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

8.  Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.

Authors:  Shaoteng Han; Takuya Fukazawa; Tomoki Yamatsuji; Junji Matsuoka; Hiroyuki Miyachi; Yutaka Maeda; Mary Durbin; Yoshio Naomoto
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

9.  Isolation of a novel member of small G protein superfamily and its expression in colon cancer.

Authors:  Wei Yan; Wen-Liang Wang; Feng Zhu; Sheng-Quan Chen; Qing-Long Li; Li Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis.

Authors:  Eun-Woo Lee; Min-Sik Lee; Suzanne Camus; Jaewang Ghim; Mi-Ran Yang; Wonkyung Oh; Nam-Chul Ha; David P Lane; Jaewhan Song
Journal:  EMBO J       Date:  2009-06-18       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.